Invivyd reported $11.8 million in PEMGARDA revenue for Q2 2025, a 413% YoY growth.
Alignment with FDA on rapid approval pathway for VYD2311 monoclonal antibody to combat COVID-19.
Positive clinical data for VYD2311 showcasing safety and effectiveness against COVID-19.
Revenue Growth
PEMGARDA revenue reached $11.8 million, showing a significant 413% growth YoY.
FDA Approval Pathway
Alignment with FDA on rapid approval pathway for VYD2311 monoclonal antibody is a critical step in COVID-19 protection efforts.
Clinical Data Success
Positive Phase 1/2 clinical data for VYD2311 demonstrates safety and effectiveness against symptomatic COVID-19.
- Invivyd aims for near-term profitability despite Q2 results.
- Focused on developing effective monoclonal antibody solutions for COVID-19 protection.
- Anticipates key milestones in pipeline development for RSV and measles vaccines.
Invivyd's dedication to developing innovative monoclonal antibodies for COVID-19 protection reflects its commitment to public health and growth in the biopharmaceutical sector.